The emerging severe acute respiratory syndrome coronavirus 2 pandemic endangers patients and physicians all over the world. The potency of COVID-19 antiviral drugs is still a matter of debate. The growing understanding of COVID-19 virology and clinical manifestations is resulting...
Open access
Research Article10.9734/jpri/2022/v34i3B35387
Entrectinib is a selective inhibitor of tyrosine kinases , tropomyosin receptor kinases that targets oncogenic rearrangements in Neurotropic Tyrosine Receptor kinase, c-ros oncogene 1 and Anaplastic lymphoma kinase used for the treatment of various solid tumors. Entrectinib gaine...
Open access
Research Article10.9734/jpri/2021/v33i44A32633
Fedratinib (INREBIC®) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis. It was approved for the first time in the United States in August 2019 to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycytha...
Open access
Research Article10.9734/jpri/2022/v34i38B36226
A simple, Precise, Accurate method was developed for the estimation of Cenobamate by RP-HPLC technique. Chromatographic conditions used are stationary phase symmetry C18 (150 mm* 4.6 mm 5 µm), mobile phase Acetonitrile: 0.01NKH2PO4in the ratio of 55:45 and flow rate was maintai...
Open access
Research Article10.9734/jpri/2021/v33i46A32848
Safeetha Shamsudheen, Vimal Mathew, B. S. Venkateswarlu, Risvana Iqubal, Mariya Palathingal, T. V. Ashira Ali, Smiya Mathew & D. Uma Maheswari·Journal of Pharmaceutical Research International·2021
Leishmaniasis is a vector-borne disease caused by flagellated protozoans belonging to the genus Leishmania. Cutaneous leishmaniasis (CL) is a parasitic disease transmitted by sandflies called phlebotomine that causes a variety of skin lesions. It has a wide range of clinical mani...
Open access
Research Article10.9734/jpri/2021/v33i60B34907